CGEM Cullinan Therapeutics, Inc.
P/E
--
Forward P/E
6.74
Price/Sales
25.86
Beta
-0.041
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Cullinan Therapeutics Reports Positive Phase 1 Data for CLN-049 in AML/MDS Patients
Cullinan Therapeutics announced updated positive data from its Phase 1 dose escalation clinical trial of CLN-049 in patients with relapsed or refractory acute...
Cullinan Oncology LLC Q3 2026 Earnings Preview: What Analysts Expect on November 05, 2026
Cullinan Oncology is expected to report a Q3 2026 net loss per share of $0.79 on zero revenue, with its current $14.54 share price trading significantly below...